Is the CSL share price a buy after the coronavirus volatility?

Is the CSL Limited (ASX:CSL) share price a buy due to the coronavirus volatility? The healthcare giant has seen its share price fall 20%.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

The CSL Limited (ASX: CSL) share price is down around 20% over the past month.

The healthcare giant hasn't been as affected as much as some of the other blue chip shares such as Commonwealth Bank of Australia (ASX: CBA) which is down around 33% over the past month.

CSL is now a lot bigger than CBA and I think it could stay like that. CBA is facing a number of uncertainties over the coming months with the economic disruption to most of the country.

But I don't think CSL is going to be as affected as much or as long as the banks, or most other blue chips in my opinion.

CSL hasn't yet given an update with the coronavirus spreading significantly across the western world.

In the half-year result the company upgraded its FY20 profit outlook so that it was in the range of approximately US$2.11 billion to US$2.17 billion, which would be growth of 10% to 13%.

CSL has previously said that because this coronavirus is quite different to the influenza virus it's not a core area of focus for CSL or Seqirus, though it is looking into "possible adjacencies in expertise, technologies and facilities that might be able to contribute to the global effort."

It has partnered with the University of Queensland's COVID-19 vaccine development program. It will provide technical expertise as well as a donation of Seqirus' proprietary adjuvant technology to their pre-clinical development program. Adjuvants are used in vaccines to create a stronger immune response and to speed vaccine production and output. The University of Queensland will use the adjuvant to test the viral protein they are developing with their molecular clamp technology.

However, the research program is just starting and it will be some months before the success of the program will be known.

Foolish takeaway

CSL is trading at 28x FY22's estimated earnings. I think that's how far ahead you need to look before the global economy may be back to normal. I think the combination of lower share price and lower interest rate makes CSL a decent long-term buy today. But I think there are shares out there with better growth prospects.

Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

a man in a business suit and carrying a laptop stands smiling with hand in pocket outside a large office building in a city environment.
Growth Shares

Buy these 2 impressive ASX 200 shares in July: experts

Experts are bullish about these two businesses.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Growth Shares

3 ASX 200 shares set to dominate the next decade

Let's see why these shares could be great long term picks for Aussie investors.

Read more »

A group of businesspeople clapping.
Growth Shares

3 ASX growth shares with 10-year compounding potential

Let's see which shares are being tipped as buys for growth investors.

Read more »

Woman happy and relaxed on a sofa at a shop.
Growth Shares

Are these 2 top ASX growth shares buys?

Are these high-flyers still buys?

Read more »

Two university students in the library, one in a wheelchair, log in for the first time with the help of a lecturer.
Growth Shares

3 stellar ASX growth shares to buy with $7,000

Let's see why analysts are feeling bullish about these top stocks.

Read more »

A smiling man at a shop counter takes payment from a customer, with racks of plants in the background.
Growth Shares

2 ASX shares to buy and hold for the next decade

I’m optimistic about what these investments can deliver in a year.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Growth Shares

High-conviction ASX 200 shares with 10-year upside

Let's see why analysts think these shares could be great long term picks.

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Growth Shares

The ultimate Australian stocks to buy and hold for 10+ years

These shares could be ultimate buys according to analysts.

Read more »